Afya (AFYA) Reaffirmed Guidance, Is The Stock Still Cheap?

Afya (AFYA) shares are in focus after the company reaffirmed its 2026 revenue guidance and reported second quarter 2026 results, while also confirming early-stage business combination talks with Yduqs Participações.

Afya's recent guidance confirmation and early-stage Yduqs talks come after a 7 day share price return of 5.90% and a 90 day share price return of 4.36%, while the 1 year total shareholder return is marginally lower and the 5 year total shareholder return is materially weaker. This suggests nearer term momentum has picked up even as longer term results have been more muted.

Compare Afya's momentum and earnings profile with 18 high quality undiscovered gems that share solid fundamentals and operate under the radar.

Afya trades at a sizeable discount to both analyst targets and one intrinsic value estimate, even after the recent share price move. Is that a sign the market is too cautious, or a fair reflection of the risks?

Most Popular Narrative: 16.8% Undervalued

Afya's most followed narrative pegs fair value at $17.25 a share compared with the last close at $14.35. That gap rests on specific growth and margin assumptions that investors need to understand.

Digital initiatives and cross-segment integration including Medical Practice Solutions and Continuing Education are increasing recurring, higher-margin digital revenues and operational synergies, which should lead to sustained net margin expansion and greater earnings stability.

Read the complete narrative.

Want the full story on why this narrative still sees upside in Afya at today’s price? The core depends on compounding revenue, rising margins and a future earnings multiple that is lower than many peers. Curious which specific long term forecasts have to land for that $17 handle to make sense?

Result: Fair Value of $17.25 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Afya's heavy exposure to medical education and softer engagement in Medical Practice Solutions mean that any shift in student demand or digital usage could quickly challenge this upside story.

Find out about the key risks to this Afya narrative.

Next Steps

Sentiment on Afya is mixed, so consider stress testing the thesis yourself against both the risks and the potential upside 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond Afya?

If you stop with Afya, you might miss opportunities that fit your goals even better. Use the Simply Wall Street Screener to compare fresh ideas side by side.

• Target potential upside with companies that combine quality fundamentals and attractive pricing by reviewing our 49 high quality undervalued stocks.
• Strengthen your income stream by assessing stocks that offer reliable payout potential through our 12 dividend fortresses.
• Prioritise resilience by checking companies that carry lower overall risk profiles using our 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com